ストックスクリーナーアプリを入手
15.44
2.70%
-0.4278
アフターアワーズ：
15.44
-0.000100
-0.00%
前日終値:
$15.87
開ける：
$15.53
24時間の取引高:
31,742
Relative Volume:
1.49
時価総額：
$20.53M
収益：
$40.93M
当期純損益:
$-23.82M
株価収益率:
-41.73
EPS:
-0.37
ネットキャッシュフロー:
$-37.87M
1週間 パフォーマンス:
-3.32%
1か月 パフォーマンス:
-8.74%
6か月 パフォーマンス:
+40.75%
1年 パフォーマンス:
-14.49%
1日の値動き範囲:
$15.37
$16.09
1週間の範囲:
$15.37
$16.97
52週間の値動き範囲:
$6.20
$22.32
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
名前
Pieris Pharmaceuticals Inc
セクター
電話
857-246-8998
住所
225 FRANKLIN STREET, BOSTON, MA
PIRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| PIRS | 15.44 | 20.53M | 40.93M | -23.82M | -37.87M | -0.37 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Pieris Pharmaceuticals Inc (PIRS) 最新ニュース
Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
How To Trade (PIRS) - Stock Traders Daily
Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - The Washington Post
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
(PIRS) Investment Analysis and Advice - Stock Traders Daily
Pieris Pharmaceuticals: Q2 Earnings Snapshot - Barchart
Pieris Pharmaceuticals director buys series F preferred stock for $1 By Investing.com - Investing.com South Africa
Pieris Pharmaceuticals director buys series F preferred stock for $1 - Investing.com
(PIRS) Technical Data - Stock Traders Daily
pieris pharmaceuticals, inc. Earnings dates - RTTNews
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - The Manila Times
Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily
(PIRS) Trading Signals - Stock Traders Daily
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewswire
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Sees Significant Decrease in Short Interest - Defense World
New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials - SciTechDaily
How the (PIRS) price action is used to our Advantage - Stock Traders Daily
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World
Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com
(PIRS) Long Term Investment Analysis - Stock Traders Daily
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World
Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News
Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve
General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News
Finansavisen - Finansavisen
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire
Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga
PIRS Stock on the Rise: A Promising Investment - The InvestChronicle
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace
Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble
Palvella and Pieris to merge - The Pharma Letter
Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch
Pieris Pharmaceuticals Inc (PIRS) 財務データ
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):